The extracellular matrix in multiple sclerosis: an update

被引:30
作者
Sobel, RA
机构
[1] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[2] Vet Affairs Hlth Care Syst, Pathol & Lab Serv, Palo Alto, CA USA
关键词
axon regeneration; central nervous system; extracellular matrix; proteoglycans; multiple sclerosis; versican;
D O I
10.1590/S0100-879X2001000500007
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Extracellular matrix (ECM) molecules play important roles in the pathobiology of the major human central nervous system (CNS) inflammatory/demyelinating disease multiple sclerosis (MS). This mini-review highlights some recent work on CNS endothelial cell interactions with vascular basement membrane ECM as part of the cellular immune response, and roles for white matter ECM molecules in demyelination and remyelination in MS lesions. Recent basic and clinical investigations of MS emphasize axonal injury, not only in chronic MS plaques, but also in acute lesions, progressive axonal degeneration in normal-appearing white matter also may contribute to brain and spinal cord atrophy in MS patients. Remodeling of the interstitial white matter ECM molecules that affect axon regeneration, however, is incompletely characterized. Our ongoing immunohistochemical studies demonstrate enhanced ECM versican, a neurite and axon growth-inhibiting white matter ECM proteoglycan, and dermatan sulfate proteoglycans at the edges of inflammatory MS lesions. This suggests that enhanced proteoglycan deposition in the ECM and axonal growth inhibition may occur early and are involved in expansion of active lesions. Decreased ECM proteoglycans and their phagocytosis by macrophages along with myelin in plaque centers imply that there is "injury" to the ECM itself. These results indicate that white matter ECM proteoglycan alterations an integral to MS pathology at all disease stages and that they contribute to a CNS ECM that is inhospitable to axon regrowth/regeneration.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 48 条
[41]   Axonal pathology in multiple sclerosis: relationship to neurologic disability [J].
Trapp, BD ;
Ransohoff, R ;
Rudick, R .
CURRENT OPINION IN NEUROLOGY, 1999, 12 (03) :295-302
[42]   Axonal transection in the lesions of multiple sclerosis [J].
Trapp, BD ;
Peterson, J ;
Ransohoff, RM ;
Rudick, R ;
Mörk, S ;
Bö, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :278-285
[43]  
Valenzuela MA, 1999, RES COMMUN MOL PATH, V104, P42
[44]   Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis [J].
Waubant, E ;
Goodkin, DE ;
Gee, L ;
Bacchetti, P ;
Sloan, R ;
Stewart, T ;
Andersson, PB ;
Stabler, G ;
Miller, K .
NEUROLOGY, 1999, 53 (07) :1397-1401
[45]   Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis [J].
Wolswijk, G .
BRAIN, 2000, 123 :105-115
[46]  
Yamaguchi Y, 2000, PROTEOGLYCANS STRUCT
[47]  
Yong VW, 1998, TRENDS NEUROSCI, V21, P75
[48]   Degradation of chondroitin sulfate proteoglycan enhances the neurite-promoting potential of spinal cord tissue [J].
Zuo, J ;
Neubauer, D ;
Dyess, K ;
Ferguson, TA ;
Muir, D .
EXPERIMENTAL NEUROLOGY, 1998, 154 (02) :654-662